✦ LIBER ✦

Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?

✍ Scribed by Keith D. Lindor; Christine H. Janes; Jeffrey S. Crippin; Roberta A. Jorgensen; E. Rolland Dickson

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 441 KB
Volume: 21
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840210219

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biliary bile acids in primary biliary ci

Biliary bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid

✍ Burton Combes; Robert L. Carithers Jr.; Willis C. Maddrey; Santiago Munoz; Guada 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed

A randomized trial comparing colchicine

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis

✍ R E Poupon; P M Huet; R Poupon; A Bonnand; J T Van Nhieu; E S Zafrani 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 1 views

The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) b

Long-term ursodeoxycholic acid delays hi

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

✍ Paul Angulo; Kenneth P. Batts; Terry M. Therneau; Roberta A. Jorgensen; E. Rolla 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 1 views

Primary biliary cirrhosis (PBC) is a progressive cholestatic liver disease frequently leading to development of cirrhosis and its complications. Ursodeoxycholic acid (UDCA) is a beneficial medical therapy for patients with PBC. Improvement in some histological features, but not in histological stage

Methotrexate (MTX) plus ursodeoxycholic

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis

✍ Burton Combes; Scott S. Emerson; Nancy L. Flye; Santiago J. Munoz; Velimir A. Lu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

This placebo-controlled, randomized, multicenter trial compared the effects of MTX plus UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC). Two hundred and sixty five AMA positive patients without ascites, variceal bleeding, or encephalopathy; a serum bilirubin less than 3 mg/dL; se

No relevant effect of ursodeoxycholic ac

No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis

✍ Karin Dilger; Annette Denk; Malte H. J. Heeg; Ulrich Beuers 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis. CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous

Differences in the metabolism and dispos

Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis

✍ Pietro Invernizzi; Kenneth D. Setchell; Andrea Crosignani; Pier Maria Battezzati 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

The clinical effectiveness of ursodeoxycholate in the treatment of liver disease may be limited by its poor absorption and extensive biotransformation. Because in vitro and in vivo studies suggest that the more hydrophilic bile acid tauroursodeoxycholate has greater beneficial effects than ursodeoxy